Pharmacopsychiatry, 55(4): 220227 Novikov M V, Snytnikova O A, Fedunov R G, Yanshole V V, Grivin V P, Plyusnin V F, Xu J, Pozdnyakov I P (2023)
doi: Almohanna HM, Ahmed AA, Tsatalis JP, Tosti A
Clinical trial results Phase 2 trial data published in the New England Journal of Medicine showed that participants receiving the highest dose of retatrutide (12mg weekly) achieved 24.2% body weight reduction over 48 weeks
The drug is known as a triple-agonist, meaning it targets three different receptors in the brain and throughout the body
AVR-352 also demonstrated higher anti-inflammatory effects in lung granulomas from mice with lung inflammation
The compound has a longer history than most patients realize